Results of the final analysis of the NeoALTTO study have been published in the European Journal of Cancer.
The NeoALTTO study was set up to investigate whether combining trastuzumab with lapatinib – given either alone, together, or one after the other – could benefit patients with human epidermal growth factor receptor 2 (HER2)-positive, breast cancer in the neoadjuvant (pre-surgical) setting.
The results of the final preplanned 10-year survival analysis of NeoALTTO and the association between pathologic complete response (pCR) and survival outcomes were published in the European Journal of Cancer in January 2023.
It was reported that patients with HER2-positive breast cancer showed a durable survival benefit of neoadjuvant anti-HER2 therapy, irrespective of treatment arm. Patients who achieved pCR have significantly sustainable better outcomes than patients without pCR.
The result was numerically greater in women treated with the drug combination and those with hormone receptor-negative tumours. There were no new or long-term safety concerns.
455 patients across 23 countries around the globe were enrolled in the NeoALTTO study. Clinical data and collected biomaterial built a huge resource for future translational research.
The NeoALTTO trial was conducted collaboratively under the Breast International Group (BIG) umbrella by the Institut Jules Bordet – Clinical Trials Support Unit / IJB-CTSU (formerly BrEAST), Frontier Science Scotland (FSS), and SOLTI and involved the participation .  The NeoALTTO study was sponsored by Novartis (Previously GSK).
